Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02879162
Title Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours
Recruitment Unknown status
Gender both
Phase Phase II
Variant Requirements No
Sponsors Canadian Cancer Trials Group
Indications
Therapies
Age Groups: adult | child | senior
Covered Countries CAN


No variant requirements are available.